science
Vanda Pharmaceuticals reports positive Phase III results for HETLIOZ in Delayed Sleep-Wake Phase Disorder
30 September 2026 - US pharmaceutical company Vanda Pharmaceuticals Inc (Nasdaq:VNDA) on Tuesday reported positive topline results from its pivotal Phase III study of HETLIOZ (tasimelteon) 20mg in adu...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories

Why this robot burns the tips off cotton plants with a Laser
Interesting Engineering

Clark Atlanta Lands Nearly $10M Pentagon Grant to Grow AI Research
Hoodline

NASA Studies Ancient Scottish Rocks To Unlock Mars’ Lost Past
The Daily Galaxy

AI predicts pancreatic cancer years before diagnosis
Earth.com

Deployable Energy to test its nuclear battery at INL's DOME
Postregister